drugset
drugset / Trial / NCT00839982

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

NCT00839982 ↗

Phase 1/2 Completed 35 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studied the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have relapsed or not responded to treatment.

Timeline

Start
2008-11
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified — Oral
Subject Cytarabine Small molecule — Subcutaneous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation myelodysplastic syndrome associated with isolated del(5q)